Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 2901-2912

  Nathwani, Dilip ^a   Cornely, Oliver A ^b   Van Engen, Anke K ^c   Odufowora Sita, Olatunji ^d   Retsa, Peny ^d   Odeyemi, Isaac A O ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c IQVIA   (United States)

^d ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Antibacterials; Economic; Model

Indexed keywords

FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG DOSE INCREASE; HUMAN; QUALITY ADJUSTED LIFE YEAR; RECURRENT INFECTION; CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; PEPTOCLOSTRIDIUM DIFFICILE; PROBABILITY; PROCEDURES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; VANCOMYCIN;

EID: 84922151992     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku257     Document Type: Article

References (45)

1. Debast SB, Bauer MP, Kuijper EJ, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl S2:1-26.
2. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140:1643-53.
3. Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect 2013; 66:115-28.
4. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81:1-14.
5. Al-Eidan FA, McElnay JC, Scott MG et al. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther 2000; 25:101-9.
6. Sears P, Crook DW, Louie TJ et al. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 2012; 55 Suppl 2: S116-20.
7. Babakhani F, Gomez A, Robert N et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60:1213-7.
8. Babakhani F, Bouillaut L, Gomez A et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 Suppl 2: S162-9.
9. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156:3354-9.
10. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-9.
11. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
12. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16:297-304.
13. Bartsch SM, Umscheid CA, Fishman N et al. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57:555-61.
14. Cornely OA, Nathwani D, Ivanescu C et al. Clinical efficacy of fidaxomicin compared with vancomycin andmetronidazole in Clostridiumdifficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69:2892-900.
15. Fekety R, McFarland LV, Surawicz CM et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33.
16. Health Protection Network. Guidance on Prevention and Control of Clostridium difficile Infection (CDI) in Healthcare Settings in Scotland. Health Protection Network Scottish Guidance 6. Health Protection Scotland, UK, 2009. http://www.his.org.uk/files/4213/7483/8488/Guidance:on_Prevention_ and_Control_of_Clostridium_difficile_Infection_CDI_in_Healthcare_Settings_ in_Scotland_Health_Protection_Network_September_2009.pdf (31 July 2011, date last accessed).
17. Scottish Antimicrobial Prescribing Group. Guidance to Optimise Antimicrobial Use and Reduce Clostridium difficile Associated Disease in Scottish Hospitals Position Paper. 2008. http://www.scottishmedicines. org.uk/files/sapg/Guidance:to_Optimise_Antimicrobial_use_and_Reduce: Clostridium_difficile_Associated_disese_in_Scottish_Hospitals.pdf (30 April 2012, date last accessed).
18. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001; 49:152-3.
19. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
20. Henrich TJ, Krakower D, Bitton A et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15:415-22.
21. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
22. Cheng A, Ferguson J, Richards M et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 2011; 194:353-8.
23. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-8.
24. Karas JA, Enoch DA, Alay SH. A review of mortality due to Clostridium difficile infection. J Infect 2010; 61:1-8.
25. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
26. Perras C, Tsakonas E, Ndegwa S et al. Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2011 (Technology report no. 136). http://www.cadth.ca/preview.php/en/hta/reports-publications/search/publication/2775 (30 April 2012, date last accessed).
27. General Register Office for Scotland. Scottish Decennial Life Tables 2000-02. http://www.gro-scotland.gov.uk/files2/stats/life-expectancyat-scotland-level/table4-scot-dlt-latest00-02.pdf (30 April 2012, date last accessed).
28. Eyre DW, Babakhani F, Griffiths D et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014; 209:1446-51.
29. Kenneally C, Rosini JM, Skrupky LP et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007; 132:418-24.
30. ISD Scotland. 2011/12 Scottish Tariffs for Cross Boundary Flow Costing. https://isdscotland.scot.nhs.uk/Health-Topics/Finance/Publications/2011-10-25/1112ScotTariffs.xls?78246552 (30 April 2012, date last accessed).
31. Personal Social Services Research Unit, Curtis L. Unit Costs of Health and Social Care 2010. http://www.pssru.ac.uk/project-pages/unit-costs/(31 December 2011, date last accessed).
32. Information Services Division Scotland. R040: Specialty Group Costs-Inpatients in All Specialties (Excluding Long Stay). http://www.isdscotland. org/Health-Topics/Finance/Costs/File-Listings-2011.asp (30 April 2012, date last accessed).
33. National Institute for Health and Care Excellence. Evidence Summary: New Medicine: Clostridium difficile Infection: Fidaxomicin. 13 July 2012. http://publications.nice.org.uk/clostridium-difficile-infection-fidaxomicinesnm1/overview (28 May 2014, date last accessed).
34. Joint Formulary Committee. British National Formulary. 61st edn. London: BMJ Group and Pharmaceutical Press, 2011.
35. Slobogean GP, O'Brien PJ, Brauer CA. Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. Acta Orthop 2010; 81:256-62.
36. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13:437-52.
37. Walker AS, Eyre DW, Wyllie DH et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012; 9: e1001172.
38. Harbarth S, Samore MH. Clostridium: transmission difficile? PLoS Med 2012; 9: e1001171.
39. Morgan OW, Rodrigues B, Elston T et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 2008; 3: e1812.
40. Sclar DA, Robison LM, Oganov AM et al. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price. Clin Drug Investig 2012; 32: e17-24.
41. Farkouh ME, Lang JD, Sackett DL. Thrombolytic agents: the science of the art of choosing the better treatment. Ann Intern Med 1994; 120:886-8.
42. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-79.
43. European Hospital and Healthcare Federation. Hospitals in Europe Healthcare Data 2011. http://www.hope.be/03activities/quality_euhospitals/eu_country_profiles/00-hospitals_in_europe-synthesis_vs2011-06. pdf (5 March 2013, date last accessed).
44. Northamptonshire Observatory. Joint Strategic Needs Assessment 2011 and Beyond. Chapter 2, Hospital Activity. 2011. http://www. northamptonshireobservatory.org.uk/projects/projectdetail.asp?projectid =145 (5 March 2013, date last accessed).
45. Wayne E, Grein J, Murthy R. Evaluation of hospital readmissions following Clostridium difficile infection (CDI) and patient characteristics associated with CDI recurrence during hospital readmission. In: Abstracts of IDWeek, San Francisco, CA, 2013. Abstract 1400. https://idsa.confex.com/idsa/2013/webprogram/Paper41261.html (29 April 2014, date last accessed).